New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data
Mechanism Exceeds Efficacy Expectations
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.
